Genetic and non-genetic determinants of outcomes in cystic fibrosis

Paediatric Respiratory Reviews

Volumn 10, Issue 1, 2009, Pages 32-36

  Wolfenden, Linda L ^a   Schechter, Michael S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cystic fibrosis; outcomes

Indexed keywords

ANTIBIOTIC AGENT; TRANSMEMBRANE CONDUCTANCE REGULATOR;

AIR POLLUTION; AUTOSOMAL RECESSIVE INHERITANCE; BURKHOLDERIA CEPACIA; CALORIC INTAKE; CHROMOSOME 7; CYSTIC FIBROSIS; DISEASE EXACERBATION; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; NONHUMAN; PANCREAS DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; PSEUDOMONAS AERUGINOSA; REVIEW; SELF CARE; SEX DIFFERENCE; SMOKING; SOCIOECONOMICS; STAPHYLOCOCCUS AUREUS; VIRAL RESPIRATORY TRACT INFECTION;

CYSTIC FIBROSIS; ENVIRONMENTAL EXPOSURE; HUMANS; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; TOBACCO SMOKE POLLUTION; TREATMENT OUTCOME;

EID: 59349085577     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2008.04.002     Document Type: Review

References (79)

1. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry, 2006 Annual Data Report. Bethesda, Maryland, 2006.
2. Rowntree R.K., and Harris A. The phenotypic consequences of CFTR mutations. Ann Hum Genet 67 (2003) 471-485
3. Rowe S.M., Miller S., and Sorscher E.J. Cystic fibrosis. N Engl J Med 352 (2005) 1992-2001
4. Noone P.G., Pue C.A., Zhou Z., et al. Lung disease associated with the IVS8 5T allele of the CFTR gene. Am J Respir Crit Care Med 162 (2000) 1919-1924
5. Gilljam M., Moltyaner Y., Downey G.P., et al. Airway inflammation and infection in congenital bilateral absence of the vas deferens. Am J Respir Crit Care Med 169 (2004) 174-179 Epub 2003 Oct 9
6. Correlation between genotype and phenotype in patients with cystic fibrosis. The Cystic Fibrosis Genotype-Phenotype Consortium. N Engl J Med 1993;329:1308-1313.
7. McKone E.F., Goss C.H., and Aitken M.L. CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest 130 (2006) 1441-1447
8. Blackman S.M., Deering-Brose R., et al. Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. Gastroenterology 131 (2006) 1030-1039 Epub 2006 Jul 24
9. Vanscoy L.L., Blackman S.M., Collaco J.M., et al. Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med 175 (2007) 1036-1043
10. Salvatore F., Scudiero O., and Castaldo G. Genotype-phenotype correlation in cystic fibrosis: the role of modifier genes. Am J Med Genet 111 (2002) 88-95
11. Drumm M.L., Konstan M.W., Schluchter M.D., et al., for the Gene Modifier Study Group. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 3531 (2005) 1443-1453
12. Gallati S. Genetics of cystic fibrosis. Semin Respir Crit Care Med 24 (2003) 629-638
13. Mekus F., Laabs U., Veeze H., and Tümmler B. Genes in the vicinity of CFTR modulate the cystic fibrosis phenotype in highly concordant or discordant F508del homozygous sib pairs. Hum Genet 112 (2003) 1-11
14. Urquhart D.S., Allen J., Elrayess M., Fidler K., Klein N., and Jaffe A. Modifier effect of the Toll-like receptor 4 D299G polymorphism in children with cystic fibrosis. Archivum Immunologiae et Therapiae Experimentalis 54 (2006) 271-276
15. O'Connor G.T., Quinton H.B., Kahn R., et al., for the Northern New England Cystic Fibrosis Consortium. Case-mix adjustment for evaluation of mortality in cystic fibrosis. Pediatr Pulmonol 33 (2002) 99-105
16. Rosenfeld M., Davis R., FitzSimmons S., Pepe M., and Ramsey B. Gender gap in cystic fibrosis mortality. Am J Epidemiol 145 (1997) 794-803
17. Verma N., Bush A., and Buchdahl R. Is there still a gender gap in cystic fibrosis?. Chest 128 (2005) 2824-2834
18. Maselli J.H., Sontag M.K., Norris J.M., MacKenzie T., Wagener J.S., and Accurso F.J. Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening. Pediatr Pulmonol 35 (2003) 257-262
19. Allen J.R., McCauley J.C., Selby A.M., et al. Differences in resting energy expenditure between male and female children with cystic fibrosis. J Pediatr 142 (2003) 15-19
20. Willis E., Miller R., and Wyn J. Gendered embodiment and survival for young people with cystic fibrosis. Soc Sci Med 53 (2001) 1163-1174
21. Truby H., and Paxton A.S. Body image and dieting behavior in cystic fibrosis. Pediatrics 107 (2001) e92
22. Adler N.E., Boyce W.T., Chesney M.A., Folkman S., and Syme S.L. Socioeconomic inequalities in health. No easy solution. JAMA 269 (1993) 3140-3145
23. Britton J.R. Effects of social class, sex, and region of residence on age at death from cystic fibrosis. BMJ 298 (1989) 483-487
24. Schechter M.S., Shelton B.J., Margolis P.A., and Fitzsimmons S.C. The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med 163 (2001) 1331-1337
25. O'Connor G.T., Quinton H.B., Kneeland T., et al. Median household income and mortality rate in cystic fibrosis. Pediatrics 111 (2003) e333-e339
26. Campbell III P.W., Parker R.A., Roberts B.T., Krishnamani M.R., and Phillips III J.A. Association of poor clinical status and heavy exposure to tobacco smoke in patients with cystic fibrosis who are homozygous for the F508 deletion. J Pediatr 120 (1992) 261-264
27. Rubin B.K. Exposure of children with cystic fibrosis to environmental tobacco smoke. N Engl J Med 323 (1990) 782-788
28. Kovesi T., Corey M., and Levison H. Passive smoking and lung function in cystic fibrosis. Am Rev Respir Dis 148 (1993) 1266-1271
29. Reijneveld S.A. The impact of individual and area characteristics on urban socioeconomic differences in health and smoking. Int J Epidemiol 27 (1998) 33-40
30. Gauderman W.J., Avol E., Gilliland F., et al. The effect of air pollution on lung development from 10 to 18 years of age. N Engl J Med 351 (2004) 1057-1067
31. Pope III C.A., Thun M.J., Namboodiri M.M., et al. Particulate air pollution as a predictor of mortality in a prospective study of U. S. adults. Am J Respir Crit Care Med 151 (1995) 669-674
32. Wheeler B.W., and Ben-Shlomo Y. Environmental equity, air quality, socioeconomic status, and respiratory health: a linkage analysis of routine data from the Health Survey for England. J Epidemiol Community Health 59 (2005) 948-954
33. Emerson J., Rosenfeld M., McNamara S., Ramsey B., and Gibson R.L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 34 (2002) 91-100
34. Nixon G.M., Armstrong D.S., Carzino R., et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 138 (2001) 699-704
35. Kosorok M.R., Zeng L., West S.E., et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 32 (2001) 277-287
36. Konstan M.W., Morgan W.J., Butler S.M., et al., for the Scientific Advisory Group, the Investigators, Coordinators of the Epidemiologic Study of Cystic Fibrosis. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 151 (2007) 134-139 139.e1. Epub 2007 Jun 22
37. Stutman H.R., Lieberman J.M., Nussbaum E., and Marks M.I. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J Pediatr 140 (2002) 299-305
38. Ratjen F., Comes G., Paul K., Posselt H.G., Wagner T.O., Harms K., and for the German Board of the European Registry for Cystic Fibrosis (ERCF). Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis. Pediatr Pulmonol 31 (2001) 13-16
39. Jones A.M., Dodd M.E., Doherty C.J., Govan J.R., and Webb A.K. Increased treatment requirements of patients with cystic fibrosis who harbour a highly transmissible strain of Pseudomonas aeruginosa. Thorax 57 (2002) 924-925
40. Tümmler B., Koopmann U., Grothues D., Weissbrodt H., Steinkamp G., and von der Hardt H. Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients. J Clin Microbiol 29 (1991) 1265-1267
41. Kosorok M.R., Jalaluddin M., Farrell P.M., et al. Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis. Pediatr Pulmonol 26 (1998) 81-88
42. Høiby N., and Pedersen S.S. Estimated risk of cross-infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients. Acta Paediatr Scand 78 (1989) 395-404
43. Pedersen S.S., Jensen T., Pressler T., Høiby N., and Rosendal K. Does centralized treatment of cystic fibrosis increase the risk of Pseudomonas aeruginosa infection?. Acta Paediatr Scand 75 (1986) 840-845
44. Kerem E., Corey M., Stein R., Gold R., and Levison H. Risk factors for Pseudomonas aeruginosa colonization in cystic fibrosis patients. Pediatr Infect Dis J 9 (1990) 494-498
45. Armstrong D., Grimwood K., Carlin J.B., et al. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol 26 (1998) 371-379
46. Mahenthiralingam E., Vandamme P., Campbell M.E., et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 33 (2001) 1469-1475 Epub 2001 Oct 4
47. De Soyza A., McDowell A., Archer L., et al. Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis. Lancet 358 (2001) 1780-1781
48. Aris R.M., Routh J.C., LiPuma J.J., Heath D.G., and Gilligan P.H. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med 164 (2001) 2102-2106
49. Stone A., and Saiman L. Update on the epidemiology and management of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, in patients with cystic fibrosis. Curr Opin Pulm Med 13 (2007) 515-521
50. Ren C.L., Morgan W.J., Konstan M.W., et al., for the Investigators, Coordinators of the Epidemiologic Study of Cystic Fibrosis. Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatr Pulmonol 42 (2007) 513-518
51. Miall L.S., McGinley N.T., Brownlee K.G., and Conway S.P. Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis. Arch Dis Child 84 (2001) 160-162
52. Smyth A.R., Smyth R.L., Tong C.Y., Hart C.A., and Heaf D.P. Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis. Arch Dis Child 73 (1995) 117-120
53. Collinson J., Nicholson K.G., Cancio E., et al. Effects of upper respiratory tract infections in patients with cystic fibrosis. Thorax 51 (1996) 1115-1122
54. Wang E.E., Prober C.G., Manson B., Corey M., and Levison H. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med 311 (1984) 1653-1658
55. Hiatt P.W., Grace S.C., Kozinetz C.A., et al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 103 (1999) 619-626
56. Conway S.P., Pond M.N., Hamnett T., and Watson A. Compliance with treatment in adult patients with cystic fibrosis. Thorax 51 (1996) 29-33
57. Quittner A.L., Espelage D.L., Ievers-Landis C., and Drotar D. Measuring adherence to medical treatments in childhood chronic illness: considering multiple methods and sources of information. J Clin Psychol Med Settings 7 (2000) 41-54
58. Abbott J., Dodd M., and Webb A.K. Health perceptions and treatment adherence in adults with cystic fibrosis. Thorax 51 (1996) 1233-1238
59. Greenberg R.N. Overview of patient compliance with medication dosing: a literature review. Clin Ther 6 (1984) 592-599
60. Koocher G.P., McGrath M.L., and Gudas L.J. Typologies of nonadherence in cystic fibrosis. J Dev Behav Pediatr 11 (1990) 353-358
61. Gudas L.J., Koocher G.P., and Wypij D. Perceptions of medical compliance in children and adolescents with cystic fibrosis. J Dev Behav Pediatr 12 (1991) 236-242
62. Patterson J.M., Budd J., Goetz D., and Warwick W.J. Family correlates of a 10-year pulmonary health trend in cystic fibrosis. Pediatrics 91 (1993) 383-389
63. Patterson J.M., McCubbin H.I., and Warwick W.J. The impact of family functioning on health changes in children with cystic fibrosis. Soc Sci Med 31 (1990) 159-164
64. DiMatteo M.R. Enhancing patient adherence to medical recommendations. JAMA 271 (1994) 79-82
65. Ievers C.E., Brown R.T., Drotar D., Caplan D., Pishevar B.S., and Lambert R.G. Knowledge of physician prescriptions and adherence to treatment among children with cystic fibrosis and their mothers. J Dev Behav Pediatr 20 (1999) 335-343
66. Lask B. Non-adherence to treatment in cystic fibrosis. J R Soc Med 87 Suppl 21 (1994) 25-27
67. Quittner A.L., Drotar D., Ievers-Landis C., Seidner D., Slocum N., and Jacobsen J. Adherence to medical treatments in adolescents with cystic fibrosis: the development and evaluation of family-based interventions. In: Drotar D. (Ed). Promoting Adherence to Medical Treatment in Childhood Chronic Illness: Concepts, Methods, and Interventions (2000), Erlbaum Associates, Mahwah, NJ
68. Anthony H., Paxton S., Bines J., and Phelan P. Psychosocial predictors of adherence to nutritional recommendations and growth outcomes in children with cystic fibrosis. J Psychosom Res 47 (1999) 623-634
69. Farrell P.M., Kosorok M.R., Rock M.J., et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Pediatrics 107 (2001) 1-13
70. Sims E.J., Clark A., McCormick J., Mehta G., Connett G., Mehta A., and for the United Kingdom Cystic Fibrosis Database Steering Committee. Cystic fibrosis diagnosed after 2 months of age leads to worse outcomes and requires more therapy. Pediatrics 119 (2007) 19-28
71. Sims E.J., Mugford M., Clark A., et al., for the UK Cystic Fibrosis Database Steering Committee. Economic implications of newborn screening for cystic fibrosis: a cost of illness retrospective cohort study. Lancet 369 (2007) 1187-1195
72. McKay K.O., Waters D.L., and Gaskin K.J. The influence of newborn screening for cystic fibrosis on pulmonary outcomes in New South Wales. J Pediatr 147 Suppl 1 (2005) S47-S50
73. Rodman D.M., Polis J.M., Heltshe S.L., et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med. 171 (2005) 621-626 Epub 2004 Dec 10
74. Lai H.C., Kosorok M.R., Laxova A., Makholm L.M., and Farrell P.M. Delayed diagnosis of US females with cystic fibrosis. Am J Epidemiol 156 (2002) 165-173
75. Farrell P., Joffe S., Foley L., Canny G.J., Mayne P., and Rosenberg M. Diagnosis of cystic fibrosis in the Republic of Ireland: epidemiology and costs. Ir Med J 100 (2007) 557-560
76. Schechter M.S., Shelton B.J., Margolis P.A., and FitzSimmons S.C. The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med 163 (2001) 1331-1337
77. Collins C.E., MacDonald-Wicks L., Rowe S., O'Loughlin E.V., and Henry R.L. Normal growth in cystic fibrosis associated with a specialised centre. Arch Dis Child 81 (1999) 241-246
78. Mahadeva R., Webb K., Westerbeek R.C., et al. Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study. BMJ 316 (1998) 1771-1775
79. Johnson C., Butler S.M., Konstan M.W., Morgan W., and Wohl M.E. Factors influencing outcomes in cystic fibrosis: a centre-based analysis. Chest 123 (2003) 20-27